ATLANTA, Sept. 3 /PRNewswire-FirstCall/ -- More than 130 cardiovascular surgeons from approximately 30 countries are scheduled to attend the second annual global Ross Summit, a two-day surgical congress focused on the highly complex Ross Procedure, which is performed on up to 1,500 individuals globally each year -- a number that is expected to increase as survival data become more widely published.
CryoLife, Inc. , a biomaterials, medical device and tissue processing company, will convene the summit at its corporate headquarters training facility in suburban Atlanta Sept. 25-26. The forum provides an opportunity to review and discuss current peer-reviewed data from the world’s experts relating to the survival advantage of the Ross Procedure and technical nuances required to perform the operation successfully.
Pioneered in 1967, by Mr. Donald N. Ross, FRCS in London, U.K., the procedure is a complex surgical technique that is performed by surgeons skilled in reconstructive cardiac surgery due to the level of technical expertise required to execute the procedure.
“However, the Ross Procedure requires very specific surgical expertise to achieve predictable, long-lasting results, and The Ross Summit was created to foster data exchange to provide a well-rounded point of view in addition to offering critical procedural training.”
Led by Professor Sir Magdi Yacoub, FRS, FRCS, of Imperial College’s Heart Science Center in London in tandem with Dr. Northrup, the Ross Summit will have a faculty of more than 30 world-renowned cardiovascular surgeons, who will present clinical data on heart reconstruction surgery at their respective clinics. The summit includes two afternoons of hands-on instruction in the various techniques of cardiac reconstruction. A full faculty list and summit agenda can be found at www.TheRossSummit.org.
About CryoLife, Inc.
Statements made in this press release or in the embedded video that look forward in time or that express management’s beliefs, expectations or hopes are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements include those regarding the expected increases in the number of Ross Procedures, expected mortality rates of patients undergoing the Ross Procedure with an experienced surgeon, expected incidents of surgical reinterventions in patients undergoing the Ross Procedure, and expected increased support for better survival rates for patients undergoing Ross Procedures than other valve replacement options. These future events may not occur as and when expected, if at all, and, together with the Company’s business, are subject to various risks and uncertainties. These risks and uncertainties are detailed in CryoLife’s Securities and Exchange Commission filings, including CryoLife’s Form 10-K filing for the year ended December 31, 2008, our Form 10-Q for the quarter ended March 31, 2009, our Form 10-Q for the quarter ended June 30, 2009, and the Company’s other SEC filings. The Company does not undertake to update its forward-looking statements.
Video: http://news.prnewswire.com/viewrelease.aspx?STORY=MTM4CryoLife, Inc.
